NCT05690581View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

October 30, 2025

Study Completion Date

February 28, 2026

Conditions
Advanced Solid Tumors and Hematologic Malignancies
Interventions
DRUG

CM369

Specified dose on specified days.

Trial Locations (3)

130000

RECRUITING

Jilin Cancer Hospital, Changchun

510060

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY